Market cap
$5 Mln
Recently Viewed
Clear All$2.26
$0.00 (0.00%)As on 22-Apr-2026 09:30EDT
Market cap
$5 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
Industry P/E
52.92
EV/EBITDA
629.5
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
2,417,314
CFO
$-0.33 Mln
EBITDA
$-0.25 Mln
Net Profit
$-1.36 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
| -42.8 | -7.2 | -26.3 | -15.4 | -11.9 | -35.3 | -- |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
| 41.2 | -47.0 | -95.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
|
2.3 | 5.3 | 5.8 | -3.4 | -40.8 | -44 | -- | 0.6 |
| 0.4 | 15.9 | 0.0 | -9.7 | -5,195.6 | -- | -- | 227.7 | |
| 2.2 | 118.7 | 190.0 | -60.3 | -15.3 | -- | -- | 23.6 | |
| 0.1 | 2.1 | 0.0 | -2.6 | -17,715.7 | -- | -- | 38.3 | |
| 16.8 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 |
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other... countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia. Read more
CEO & Director
Mr. Su-Leng Tan
CEO & Director
Mr. Su-Leng Tan
Headquarters
Kuala Lumpur
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of BioNexus Gene Lab Corp Common stock (BGLC) is $2.26 (NASDAQ) as of 22-Apr-2026 09:30 EDT. BioNexus Gene Lab Corp Common stock (BGLC) has given a return of -11.85% in the last 3 years.
Since, TTM earnings of BioNexus Gene Lab Corp Common stock (BGLC) is negative, P/E ratio is not available.
The P/B ratio of BioNexus Gene Lab Corp Common stock (BGLC) is 0.62 times as on 17-Apr-2026, a 81 discount to its peers’ median range of 3.21 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-3.15
|
0.60
|
|
2023
|
-3.23
|
0.88
|
|
2022
|
-2.67
|
0.14
|
|
2021
|
2.83
|
0.30
|
The 52-week high and low of BioNexus Gene Lab Corp Common stock (BGLC) are Rs 15.60 and Rs 1.92 as of 23-Apr-2026.
BioNexus Gene Lab Corp Common stock (BGLC) has a market capitalisation of $ 5 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in BioNexus Gene Lab Corp Common stock (BGLC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.